Department of Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino - IST - Istituto Nazionale Per La Ricerca Sul Cancro, 16132 Genova, Italy.
Melanoma Res. 2013 Jun;23(3):196-8. doi: 10.1097/CMR.0b013e3283610586.
The purpose of the present study was to retrospectively evaluate the safety and activity of intravenous fotemustine in patients with metastatic uveal melanoma. We report on a series of 25 consecutive patients diagnosed with metastatic uveal melanoma. Fotemustine was administered intravenously as a first-line treatment to all patients. Thrombocytopenia and leukopenia (any grade) were observed in 60 and 52% of patients, respectively. Only two patients discontinued treatment because of toxicity (G3 thrombocytopenia), whereas all other patients were discontinued for progressive disease. Two partial responses were observed. Nine patients had stable disease (disease control rate=44%). The median survival duration was 13.9 months, and the 1-year survival rate was 60%. Intravenous fotemustine is well tolerated and could improve the outcome of metastatic uveal melanoma patients with or without liver involvement, although a randomized prospective trial is required to confirm these results.
本研究的目的是回顾性评估转移性脉络膜黑色素瘤患者静脉注射福莫司汀的安全性和疗效。我们报告了一系列 25 例连续诊断为转移性脉络膜黑色素瘤的患者。所有患者均接受静脉注射福莫司汀作为一线治疗。分别有 60%和 52%的患者出现血小板减少和白细胞减少（任何级别）。仅有 2 例患者因毒性（G3 血小板减少）而停止治疗，而所有其他患者均因疾病进展而停止治疗。观察到 2 例部分缓解。9 例患者病情稳定（疾病控制率=44%）。中位生存时间为 13.9 个月，1 年生存率为 60%。静脉注射福莫司汀耐受性良好，可改善伴或不伴肝转移的转移性脉络膜黑色素瘤患者的预后，尽管需要进行随机前瞻性试验来证实这些结果。
